CBT-004, a new drug for the treatment of congestive macula, completed Phase II clinical trial in the US and the first patient was enrolled

21/5000 The National Health Commission issued the Standards for the Establishment of National Laboratory Medicine Centers

Abbvie acquires ADC pioneer ImmunoGen for $10.1bn

Tilpotide is crossing over again